The Swiss Society of Nephrology (SGN) advocates targeted screening for defined risk groups. However, given the prevalence of chronic kidney disease (CKD) in primary care, it is hardly possible to refer everyone affected to a nephrologist. Clear risk stratification is therefore essential. Drug therapy is based on several pillars and aims to slow down the rate of progression of GFR decline on the one hand and to reduce the cardiovascular risk on the other.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- HER2-positive breast cancer
ENPP1 as a biomarker for poor prognosis and early detection of brain metastases
- Update 2025
Hypercholesterolemia
- GPP: from molecular principles to targeted therapy
Therapeutic rationale for targeted IL-36 receptor inhibition
- HFpEF 2025
Precision medicine and phenotypes
- Myelofibrosis
New treatment options for myelofibrosis patients with a high risk of anemia?
- Chronic insomnia in adults: Guideline recommendations
CBT-i as first choice – pharmacotherapy as secondary intervention
- COPD therapy
Drug therapy – Update 2025
- Pulmonary hypertension